About IPO
IPO is a process by which private companies go public for the first time and their shares are listed (open for buying and selling) in the stock market. IPO helps investors get the first mover advantage and also assists companies to assess their net worth in the primary market.
Benefits of IPO to Investors
-
Opportunity to invest in new companies or startups, otherwise not accessible to general public
-
Allows buying shares at a discount to the market price (post listing)
-
Possibility of significant listing gains, especially in IPOs of high growth companies
-
Absolute transparency with all critical information available in the draft red herring prospectus.
Who can invest in IPO?
While any individual can invest in IPO, there are three distinct categories of IPO investors:
-
Institutional investors or Qualified institutional investors
Commercial banks, mutual fund houses, pension funds, foreign portfolio, trusts, etc. QII allotment is capped at 50% by SEBI.
-
High networth investors
Non-Qualified institutional investors with net worth of more than ₹2 lakhs. Allotment for HNIs is capped at 15% of the overall subscription.
-
Retail investors
Investors with net worth of less than ₹2 lakhs. Minimum allotment capped at 35%.
How to apply for IPO @
How to enhance chances of IPO allotment?
News
-
PropShare Platina REIT IPO subscribed 3%
The initial public offer (IPO) of Property Share Investment Trust SM REIT (PropShare Platina) received bids for 90 shares as against 3,353 shares on offer, as per the Bombay Stock Exchange (BSE) website data at 17:03 IST on 2 December 2024. The issue was subscribed 0.03 times.
The issue opened for bidding today, 2 December 2024 and it will close on Wednesday, 4 December 2024. The price band of the IPO is fixed at Rs 10 lakh to 10.50 lakh.
The IPO comprises a fresh issue of 3353 equity shares, aggregating up to Rs 353 crore.
The proceeds from the offer will be utilised towards acquisitions of the real estate properties by the SPVs as commercial office spaces by way of lending to the Platina SPVs or subscribing to the equity and debt instruments of our SPVs and general purposes.
The Property Share Investment Trust (REIT) is India's first registered Small and Medium Real Estate Investment Trust. The object and purpose of the REIT is to carry on the activity of a small and medium real estate investment trust through oneor more Schemes, as permitted under the REIT Regulations.
Each Scheme may have its own investment objectives, in accordance with the REIT Regulations. The investment of the Schemes shall only be in completed and revenue generating real estate properties through SPVs.
Powered by Capital Market - Live News
-
Suraksha Diagnostics IPO subscribed 25%
The initial public offer (IPO) of Suraksha Diagnostics received 34,00,068 bids for shares as against 1,34,32,533 shares on offer, according to stock exchange data at 17:00 IST on Monday (2 December 2024). The issue was subscribed 0.25 times.
The issue opened for bidding on Friday (29 November 2024), and it will close on Tuesday (03 December 2024). The price band of the IPO was fixed between Rs 420 and 441 per share. An investor can bid for a minimum of 34 equity shares and in multiples thereof.
The IPO comprises an offer for sale of 1,91,89,330 equity shares, aggregating up to Rs 846.25 crore.
The promoters and promoter group hold an aggregate of 3,18,02,034 equity shares, aggregating to 61.07% of the pre-offer issued and paid-up equity share capital. Their post-IPO shareholding is expected to be around 48.78%.
Ahead of the IPO, Suraksha Diagnostics on Thursday, 28 November 2024, raised Rs 253.87 crore from anchor investors. The board allotted 57.56 crore shares at Rs 441 each to 16 anchor investors.
Suraksha Diagnostics offers a one-stop integrated solution for pathology, radiology testing, and medical consultancy services, providing a comprehensive range of over 2,300 tests across various specialties and disciplines, as of June 30, 2024.
The diagnostic test menu includes (a) 788 routine pathology tests, covering basic biochemistry and hematology to 664 specialized tests like advanced biochemistry, histopathology, and molecular pathology, and (b) 766 basic/intermediate radiology tests, including x-rays, ultrasonography (USG), and CT scans, along with 119 advanced radiology tests like MRI scans and specialized CT scans. Radiology equipment consists of 24 CT and 13 MRI machines.
The firm reported a consolidated net profit of Rs 7.94 crore and sales of Rs 60.73 crore for the three months ended on 30 June 2024.
Powered by Capital Market - Live News
-
Suraksha Diagnostics IPO subscribed 11%
The initial public offer (IPO) of Suraksha Diagnostics received 14,58,872 bids for shares as against 1,34,32,533 shares on offer, according to stock exchange data at 17:00 IST on Friday (29 November 2024). The issue was subscribed 0.11 times.
The issue opened for bidding on Friday (29 November 2024), and it will close on Tuesday (03 December 2024). The price band of the IPO was fixed between Rs 420 and 441 per share. An investor can bid for a minimum of 34 equity shares and in multiples thereof.
The IPO comprises an offer for sale of 1,91,89,330 equity shares, aggregating up to Rs 846.25 crore.
The promoters and promoter group hold an aggregate of 3,18,02,034 equity shares, aggregating to 61.07% of the pre-offer issued and paid-up equity share capital. Their post-IPO shareholding is expected to be around 48.78%.
Ahead of the IPO, Suraksha Diagnostics on Thursday, 28 November 2024, raised Rs 253.87 crore from anchor investors. The board allotted 57.56 crore shares at Rs 441 each to 16 anchor investors.
Suraksha Diagnostics offers a one-stop integrated solution for pathology, radiology testing, and medical consultancy services, providing a comprehensive range of over 2,300 tests across various specialties and disciplines, as of June 30, 2024.
The diagnostic test menu includes (a) 788 routine pathology tests, covering basic biochemistry and hematology to 664 specialized tests like advanced biochemistry, histopathology, and molecular pathology, and (b) 766 basic/intermediate radiology tests, including x-rays, ultrasonography (USG), and CT scans, along with 119 advanced radiology tests like MRI scans and specialized CT scans. Radiology equipment consists of 24 CT and 13 MRI machines.
The firm reported a consolidated net profit of Rs 7.94 crore and sales of Rs 60.73 crore for the three months ended on 30 June 2024.
Powered by Capital Market - Live News
-
NSE SME IPO of Apex Ecotech subscribed 1.75 times
The initial public offer (IPO) of Apex Ecotech received bids for 44,08,000 shares as against 25,10,400 shares on offer, as per NSE data as of 17:00 hours on 27 November 2024. The issue was subscribed 1.75 times.
The issue opened for bidding on 27 November 2024 and it will close on 29 November 2024. The price band of the IPO is fixed at Rs 71 to Rs 73 per share. The minimum order quantity is 1,600 equity shares. The equity shares will list on NSE's SME platform.
The IPO comprises fresh issue of 34,99,200 shares. The promoter and promoter group shareholding will dilute to 69.29% from 94.32% pre-IPO.
About 2,00,000 equity shares will be reserved for subscription by market maker to the issue. The net issue comprises of 32,99,200 equity shares. The issue and the net issue will constitute 26.54% and 25.02% respectively of the post offer paid up equity share capital of the company.
The company intends to utilize the net proceeds for working capital requirements of company, public issue expenses and for general corporate purpose.
Ahead of the IPO, Apex Ecotech on Tuesday, 26 November 2024, raised Rs 7.21 crore from anchor investors. The board allotted 9.88 lakh shares at Rs 73 per share to 4 anchor investor.
Apex Ecotech provides water and wastewater treatment, recycling, and reuse solutions. The company also offers its customers after-sales support as well as operation and maintenance services. The company's services include setting up raw water treatment plants for industrial processes, effluent & sewage treatment plants to meet pollution norms, providing sludge dewatering equipment, recycling of pre-treated wastewater through membrane systems (ultra filtration, nanofiltration, reverse osmosis, disc type RO, etc.) and thermal / vapor compression- based evaporators & crystallizers for zero liquid discharge systems. The company had 119 full time employees.
The company recorded revenue from operations of Rs 21.70 crore and net profit of Rs 1.55 crore for the period as on 30 September 2024.
Powered by Capital Market - Live News
-
Enviro Infra Engineers IPO ends with nearly 90x subscription
The initial public offer (IPO) of Enviro Infra Engineers received 2,76,83,39,401 bids for shares as against 3,07,93,600 shares on offer. The issue was subscribed 89.90 times.
The Qualified Institutional Buyers (QIBs) category was subscribed 157.05 times. The Non-Institutional Investors (NIIs) category was subscribed 153.80 times. The Retail Individual Investors (RIIs) category was subscribed 24.48 times.
The issue opened for bidding on 22 November 2024, and it closed on 26 November 2024. The price band of the IPO was fixed between Rs 140 and 148 per share.
The IPO comprised a fresh issue of up to 3,86,80,000 equity shares of Rs 10 each and an offer for sale of up to 52,68,000 equity shares of Rs 10 face value each.
Of the net proceeds from the fresh issue, Rs 31.45 crore will be used for the prepayment or repayment of certain outstanding borrowings, investment in subsidiaries HPPL, STBFL, and JPPL for funding working capital requirements, and general corporate purposes.
As of 30 June 2024, total outstanding stood at Rs 305.59 crore, and this includes unsecured loans of about Rs 49.18 crore.
Ahead of the IPO, Enviro Infra Engineers on Thursday, 21 November 2024, raised Rs 194.68 crore from anchor investors. The board allotted 1.31 crore shares at Rs 148 each to 22 anchor investors.
Enviro Infra Engineers (EIEL) is in the business of designing, construction, operation, and maintenance of water and wastewater treatment plants (WWTPs) and water supply scheme projects (WSSPs) for government authorities and bodies. WWTPs include Sewage Treatment Plants (STPs), Sewerage Schemes (SS), and Common Effluent Treatment Plants (CETPs), while WSSPs include Water Treatment Plants (WTPs) along with pumping stations and the laying of pipelines for water supply.
The company participates in tenders floated by state governments and ULBs for developing WWTPs and WSSPs on an EPC or HAM basis. Till 30 June 2024, the company has successfully developed 28 WWTPs and WSSPs across India in the last seven (7) years, including 22 projects of 10 MLD capacity and above.
The firm reported a consolidated net profit of Rs 28.16 crore and sales of Rs 205.18 crore for the three months ended on 30 June 2024.
Powered by Capital Market - Live News